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Docetaxel (Taxotere) is an effective drug against various malignancies, including ovarian, 
breast, non-small cell lung cancer (Ringel and Horwitz, 1991). Lipophilic nature of 
docetaxel made it difficult for parenteral administration. Hence, different pharmaceutical 
methodologies are applied to make the drug suitable for parenteral administration. Use of 
surfactants is one of the most frequently used methods for the preparation of docetaxel 
formulation for parenteral administration. But the instability of the drug in surfactant and 
harsh or toxic effects of surfactants made scientists to search for alternative delivery systems. 
Eventhough docetaxel is a lipophilic drug; its transport across the blood brain barrier (BBB) 
is limited because of p-gp, acts as an efflux pump to limit the drug transport to brain 
(Kemper et al., 2004). Hence, its use in breast cancer is predominant but use in breast cancer 
induced brain metastasis is limited. Eventhough, co-administration of p-gp inhibitors has 
shown improved efficacy of docetaxel, side effects of these inhibitors made their use limited 
in therapy. Based on these points, attempts were made to prepare a versatile/different 
delivery system with good stability, minimum toxic effects and brain targeting efficiency. 
Liposomes (Immordino et al., 2003), cyclodextrins (Grosse et al., 1998), and nanoparticles 
(Musumeci et al., 2006) were already attempted for resolving the above-mentioned 
problems. But limitations of these formulations, such as lower encapsulation efficiency, 
limited solubilized capacity, poor physicochemical stability, and complex preparation 
procedures made them still questionable. Hence, Solid lipid nanoparticles (SLN) are chosen 
to prepare an alternative delivery system for docetaxel because it has many advantages over 
other nanoparticulate systems, such as biocompatibility, physical stability and ease of 
preparation, SLN can also increase the solubility, absorption and bioavailability of most of 
the lipophilic drugs (Muller et al., 2000). Nano-size of SLN can make it easy for the 
parenteral administration. SLNs are also more efficient targeting systems for brain disorders 
than any other delivery systems (Manjunath et al., 2005). Lipophilic nature and high 
entrapment of lipophilic drugs in SLN can make the drugs easy to cross the Blood-Brain 
Barrier (BBB).  
Physicochemical properties of drugs, specifically, solubility determines the loading capacity, 
performance and stability or retention of drug in the formulation (Lipinski et al., 1997; 
Kreilgaard, 2002; Bhattachar et al., 2006). Hence, saturation solubility of docetaxel in water 
and phosphate buffer at various pHs were studied. Docetaxel has shown limited solubility in 
water (4.79 ±0.04µg/mL) and phosphate buffer (4.98±0.08µg/mL at pH 7.4). This makes the 
drug difficult to formulate as stable lipid formulation. Eventhough, lipid formulations were 
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prepared, the drug leakage from the system makes the formulation unstable. Based on the 
lipophilicity, drug was loaded in lipid nanoparticles made up of glyceryl monostearate 
(GMS). For the preparation of docetaxel loaded SLN, different surfactants were used to 
study the effect of surfactant on in-vitro properties of nanoparticles. Tween 80, Brij 97, 
Poloxamer 188 and low molecular weight PVA were selected for the preparation of solid 
lipid nanoparticles. Process (homogenization time and sonication time) and formulation 
parameters (amount of lecithin, surfactant concentration and drug loading) involved in 
solvent emulsification and evaporation method were optimized in order to get minimum 
particle size with maximum entrapment efficiency. Phospholipids, such as lecithin, are the 
first candidates as emulsifiers because of their biocompatibility and long term application of 
lipid formulations. Hence, lecithin was used as one of the surfactant for the formulation of 
solid lipid nanoparticles. Homogenization and sonication time were optimized as 3 min and 
10 min respectively. Beyond these, statistically insignificant change in particle size was 
observed. But, increase in sonication beyond 20 min resulted in increase in particle size after 
cooling the nanoemulsion at room temperature. To optimize the emulsifier concentration, 
different concentrations (0.5, 1, 1.5 and 2%) of surfactants were studied. Increase in 
concentrations of surfactant led to increase in particle size. Based on the results obtained 
1.5% Tween 80, 1.5% Brij 97, 1% Poloxamer 188 and 1% PVA were optimized 
concentrations for the preparation of solid lipid nanoparticles. Blank and drug loaded solid 
lipid nanoparticles were prepared using above optimized conditions. These results clearly 
suggested that an optimum concentration of surfactant was needed to cover the surface of 
nanoparticles effectively to prevent agglomeration during the homogenization and sonication 
processes. PVA containing nanoparticles has shown more size compared with all other 
formulations. Significant increase in particle size was observed in all cases when compared 
docetaxel loaded SLN with blank SLN. Nanoparticles prepared with Tween 80 and Brij 97 
have shown small particle size (47.57±1.57 nm and 56.91±1.22 nm) compared with other 
formulations. Zeta potential of GEDT was -31.7±4.46 mv and GEDB was -24.6±2.70 mv. This 
is a key factor to evaluate the stability of colloidal dispersion through the electrostatic 
repulsion between the particles. High absolute value of the Zeta potential indicates high 
surface charge of the SLNs, which leads to strong repellent interactions among the SLNs in 
dispersion and thus high stability. Drug loading capacity of solid lipid nanoparticles was 
determined by adding different amounts of drug (5, 10 and 15 mg) to organic phase. At 
different drug loadings, entrapment efficiency of the formulation was determined. At 5 mg, 
all the formulations have shown 100% entrapment efficiency. But increase in drug loading to 
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10 mg resulted in decrease in percentage of entrapment efficiency. Optimized formulations 
have shown 73.07± 0.75 % (Tween 80), 74.81± 1.66% (Brij 97), 60.33± 0.73 % (Poloxamer 
188) and 70.2± 0.94% (PVA) of entrapment efficiency at 10 mg of drug loading. In 
comparison with other surfactants used in the study, Tween 80 and Brij 97 has shown more 
entrapment of docetaxel in SLN. This low entrapment of drug in monostearin nanoparticles 
is because of low lipophilicity that causes drug to partition between aqueous phase and lipid 
phase. To increase the drug loading in SLN drug was dissolved in alpha- tocopherol and 
added to the lipid phase. Docetaxel is having good solubility in Vitamin E (~75.0±1.8 
mg/mL), hence alpha-tocopherol was added to lipid phase (Loan Huynh et al., 2008). An 
amount of 20 mg of tocopherol and 80 mg of GMS containing lipid phase showed significant 
increase in entrapment with all surfactants compared with SLN prepared without tocopherol 
(Table 1.3 A and B). Tocopherol containing formulations have shown more than 90% of 
entrapment of docetaxel. At 10 mg drug loading, optimized formulations containing 
tocopherol prepared with Tween 80 (GEDT), Brij 97 (GEDB), Poloxamer 188 (GEDP) and 
PVA (GEDPV) showed 99.07± 0.42%, 98.81± 0.72%, 90.42± 0.78% and 97.03± 1.81% 
respectively. Because of increased solubility of docetaxel in tocopherol, increased 
entrapment of docetaxel was observed in formulations containing tocopherol (Table 1.3B 
and Fig 1.2). Further increase in drug loading to 15mg showed decreased entrapment 
efficiency (Table1.4). GEDP has sown less entrapment efficiency compared with other 
formulations (p<0.05). No significant difference in EE was observed with Tween 80 and Brij 
97 based docetaxel loaded tocopherol containing SLN formulations. Based on the size and 
entrapment efficiency results, tocopherol-containing SLN stabilized with Tween 80 and Brij 
97 have shown minimum particles and narrow size distribution with high encapsulation 
efficiency. TEM analysis of the optimized GEDT and GEDB showed almost spherical shape 
of nanoparticles. Crystalline studies of GMS indicated less order crystalline structure and 
favors high drug inclusion compared with highly ordered crystalline lipids. This is the reason 
for more amount of drug in monostearin SLN. PXRD studies of formulation have shown 
decreased intensity of lipid and drug peaks in both formulations. Small particle size and the 
presence of emulsifiers may also retards the crystallinity of lipid (Mehnert and Mader, 
2001). This reduced intensity indicating the decreased crystallinity of lipid, which favors 
successful drug incorporation. These XRD patterns also indicated that the total drug was 
entrapped in SLN as amorphous form (Fig 2.8 A-C). Lipids of less ordered crystal lattices 
favor successful drug inclusion, compared to those prepared using highly ordered crystal 
packing lipids (Manjunath et al., 2005). Less ordered lipids also prevents the drug expulsion 
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from the particles. Hence, GMS provides mores space for the accommodation of drug 
molecule and limits drug expulsion. These results are also correlating with stability. 
Percentage decrease in entrapment efficiency and increase in particle size were very less in 
formulations stabilized with Tween 80 and Brij 97. Entrapment efficiency of all formulations 
was decreased when these formulations were stored at refrigerated temperature for three 
months. Eventhough stability of PVA stabilized SLN was good, large particle size of formed 
nanoparticle made it less appropriate compared with GEDT and GEDB formulations. In-
vitro release studies conducted with GEDT and GEDB in PBS have showed the controlled 
release of drug from the nanoparticles. These formulations resulted initial burst release of 
drug from the particles followed by controlled release. GEDT and GEDB have shown about 
30% of drug release from the nanoparticles in 72 h. The slow release of drug may be due to 
the long fatty acid chain length of GMS (Borgstrom, 1975). SLN stabilized with Tween 80 
has shown less drug release at every time point compared with Brij 97. Release data of both 
the formulations were closely fitted in Higuchi non-linear kinetic model than zero and first 
order. Release of docetaxel from the formulation followed non-fickian diffusion. In this 
mechanism, one or more process such as erosion and diffusion were involved in drug release 
from the nanoparticles. 
Cytotoxicity of GEDT and GEDB was studied in neuroblastoma (U373) and breast cancer 
(MCF-7) cell lines. Cytotoxicity studies revealed the IC50 value of free drug was more 
compared SLN formulation. Blank SLN prepared with both the surfactants have not 
shown any cytotoxicity within the concentration range. GEDT and GEDB formulations 
have shown less IC50 values, about 10 and 4 times less compared with free drug in U473 
celllines respectively. These formulations also showed 15 times decrease in IC50 value 
with GEDT and 8 times decrease with GEDT in MCF-7 cell lines. Reason for the more 
cytotoxicity of SLN formulation is due to the more uptake of drug into the cells compared 
with free drug. Drug uptake studies also revealed more drug uptake with SLN 
formulations. But drug uptake with free drug and SLN were lower in U373 compared 
with MCF-7. The reason may be because of the astrocytes and tight junctions present in 
the neuroblastoma cells compared with breast cancer cell lines. Between GEDT and 
GEDB, Tween 80 stabilized SLN has shown more drug uptake and less IC50 value than 
GEDB. Hence, GEDT was selected for in vivo toxicity studies. It was observed in in-vivo 
toxicity studies that the pattern of body weight loss and subsequent gain for the rats in 
GEDT (medium and high doses) and Taxotere (medium and high dose) were almost 
similar. Hematological studies resulted that the GEDT has shown significantly less 
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percentage decrease in WBC and Plate count compared with Taxotere. Hence, 
myelosupression is significantly less with GEDT compared with Taxotere. Behavioral 
studies have shown similar pattern of hair loss with both GEDT and Taxotere. At high 
doses, Taxotere resulted in mortality with MST of 9 days. But GEDT has not shown any 
mortality even at high doses. Hence, GEDT(D-SLN) was selected for further surface 
modification studies to target the drug to brain. 
Beta hydroxyl butyric acid (HBA) is a well known ketone body utilized as energy source 
by brain. The movement of HBA across the brain is by both diffusion and carrier 
mediated transport. Monocarboxylic acid transport system present in brain is responsible 
for the transport of HBA across the BBB. Hence, HBA was selected as a ligand for 
targeting D-SLN to brain. Thiolated chitosan is one of the polymer used for the surface 
modification of D-SLN in another study for brain targeting. Because of improved 
solubility and mucoadhesive properties coupled with p-gp inhibition, thiolated chitosan 
also was selected for surface modification to target brain. 
Hydrophilic nature and negative charge of HBA made it in appropriate to incorporate or coat 
the SLN. Hence, to improve the lipophilicity to incorporate in SLN, lipophilic conjugate of 
HBA was prepared with stearylamine (SA). Conjugate of HBA and SA (SA-HBA) was 
synthesized using EDC coupling reaction. The formation of conjugate was confirmed using 
1H-NMR, FT-IR and mass spectroscopy. This SA-HBA conjugate was incorporated in D-
SLN to prepare HBA modified docetaxel loaded SLN (HD-SLN). Similarly, thiolated 
chitosan was synthesized by EDC coupling between chitosan and thioglycolic acid (TGA). 
Formation of thiolated polymer was confirmed by measuring thiol groups present in chitosan 
conjugate with Ellmans reagent. The obtained thiolated chitosan displayed about 460 µM 
thiol groups per gram polymer. Because of its positive charge, thiolated chitosan was coated 
on negatively charged D-SLN by electrostatic interaction. Thus formed thiolated chitosan 
coated nanoparticles were designated as TD-SLN. These nanoparticles have shown positive 
charge, which is a sign for surface modification of D-SLN. 
Surface modification of D-SLN with both SA-HBA and chitosan-TGA conjugate was further 
confirmed by XPS analysis. XPS analysis of D-SLN revealed presence of carbon and 
oxygen on the surface on nanoparticle. But, HD-SLN has shown the presence of nitrogen on 
the nanoparticle. This nitrogen belongs to SA-HBA conjugate. Hence, D-SLN was surface 
modified with SA-HBA. Similar results were obtained with TD-SLN. Thiolated chitosan 
coated D-SLN showed both sulfur and nitrogen on the surface on SLN. These two elements 
belong to the thiolated chitosan. Based on these results it was confirmed the surface of D-
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SLN was modified with SA-HBA and thiolated chitosan to obtain HD-SLN and TD-SLN 
respectively. These two formulations have shown increased particle size compared with D-
SLN. In HD-SLN, addition of SA-HBA to lipid phase increased the viscosity of lipid phase 
and resulted in increased particle size (88.43±3.79 nm), where as in TD-SLN, coating of 
polymer on D-SLN is the reason for increased particle size (118.43±7.52 nm). Because of 
adsorption of polymer layer on the SLN, TD-SLN has shown larger particle size compared 
with HD-SLN. Addition of SA-HBA in lipid phase significantly decreased (p<0.05) the 
entrapment of docetaxel in HD-SLN (95.77±1.84%) compared with D-SLN (99.79±0.12%), 
but statistically insignificant difference (p>0.05) in entrapment efficiency was observed with 
TD-SLN (97.33±1.94%) compared with D-SLN. Crystalline studies of both the formulations 
have shown decreased crystallinity compared with pure drug and lipid. This revealed that the 
docetaxel was present as an amorphous form in the nanoparticle. The less ordered crystalline 
form of lipid also resulted in stable SLN formulation with good entrapment efficiency 
(94.62±0.98% with HD-SLN and 95.28±1.44% with TD-SLN)  for six months at 2-8°C. 
Stability studies also revealed the increase in particle size with D-SLN (12%), HD-SLN 
(16%) and TD-SLN (7%) after six months. Because of its positive charge on SLN, TD-SLN 
has shown more stability than other SLN formulations. Surface modified SLN have shown 
more controlled release of drug from the SLN compared with D-SLN. Surface modification 
of SLN led to increase the particle size and made the drug present in the nanoparticle to 
travel a long distance to diffuse from the SLN. This increased distance to travel drug through 
the lipid core resulted in controlled release of drug form HD-SLN and TD-SLN. Because of 
larger particle size of TD-SLN, drug release from TD-SLN was slow compared with HD-
SLN in every time point. D-SLN, HD-SLN and TD-SLN showed 16.8±1.0%, 12.4±1.1% 
and 10.5±1.0% release of docetaxel in 24 h. Hence, the drug was associated with 
nanoparticles for more time and taken up by cells as the particle rather than as free drug 
(Zhenghong et al., 2009). HD-SLN and TD-SLN have shown Higuchi non-linear kinetic 
pattern of release and non-fickian diffusion with n value 0.6 and 0.8 with HD-SLN and TD-
SLN respectively. Hence, the mechanism involved in the release of drug from SLN was both 
erosion and diffusion.  
Cytotoxicity studies of HD-SLN and TD-SLN also revealed the decrease in IC50 values 
compared with free drug and D-SLN. Similar to D-SLN, both HD-SLN and TD-SLN have 
shown more cytotoxicity in MCF-7 compared with U373. Both the formulations have shown 
about 20% decrease in IC50 values compared with D-SLN in U373 cell lines. But HD-SLN 
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has shown 33 times and TD-SLN has shown 24 times decrease in IC50 values compared with 
D-SLN in MCF-7 celllines. No significant difference in IC50 values in U373 celllines was 
observed both with HD-SLN and TD-SLN. But HD-SLN has shown more cytotoxicity and 
less IC50 value in MCF cells compared with TD-SLN. Because more utilization of ketone 
bodies by tumor cells, uptake of HBA was more in MCF compared with U373.  Surface 
modified SLN has shown about 2 times more drug uptake compared with D-SLN in both the 
celllines. 
Pharmacokinetic studies of marketed formulation (Taxotere), D-SLN, HD-SLN and TD-
SLN were studied in male Wistar rats after i.v. administration. D-SLN and HD-SLN have 
shown significantly high Cmax (p<0.05) compared with Taxotere. But the Cmax of Taxotere 
(6.74±0.78 µg/mL)  and TD-SLN (7.5±0.67 µg/mL) were shown statistically insignificant 
difference. Reason for the difference in Cmax among the SLN was more distribution of 
docetaxel to other tissues with TD-SLN (7.5±0.67 µg/mL) compared with D-SLN 
(10.46±1.24 µg/mL) and HD-SLN (9.81±0.28 µg/mL). But statistically significant increase 
in AUC was observed with SLN formulations compared with Taxotere. Rapid distribution of 
TD-SLN to tissues compared with D-SLN and HD-SLN is the reason for less AUC of TD-
SLN (28.52±5.0 µg-h/mL) compared with D-SLN (62.72±5.63 µg-h/mL) and HD-SLN 
(59.52±6.34 µg-h/mL). Increased t1/2 and MRT values revealed the controlled release of 
docetaxel from SLN compared with Taxotere. Distribution of SLN to tissues led to increased 
drug concentration in different tissues compared to free drug. Docetaxel loaded SLN have 
shown increase docetaxel concentrations in brain compared with Taxotere. Because of low 
particle size SLN can be taken up by brain easily compared with free drug. But surface 
modification with HBA and thiolated chitosan resulted in increased brain concentrations 
compared with both D-SLN and free drug. AUC of HD-SLN (3.86±0.42 µg-h/mL) and TD-
SLN (4.62±0.63 µg-h/mL ) were more in brain compared with D-SLN (2.28±0.89 µg-h/mL) 
and Taxotere (0.518±0.15 µg-h/mL ). About 8 to 9 times increase in AUC of brain was 
observed with HD-SLN and TD-SLN compared with Taxotere. This may be because of 
monocarboxylic acid carrier system; the uptake of HD-SLN was increased compared with D-
SLN and free drug. Similarly, because of p-gp inhibition at BBB, brain uptake of TD-SLN 
was increased. But, in between HD-SLN and TD-SLN, statistically no significant difference 
was observed in AUC of drug in brain. Tissue distribution studies also revealed the 
distribution of drug to other tissues. SLN formulations have shown more uptake of drug in 
spleen compared with free drug (p<0.05). This may be because of the uptake of 
nanoparticles by microphages. Similar results were also observed in liver. But TD-SLN has 
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shown statistically insignificant difference in liver uptake. Distribution of more docetaxel to 
brain and RES organs such as spleen made the decrease distribution of drug to heart.  This 
decreased docetaxel concentration in heart with SLN formulations may help in decreased 
cardio-toxicity of docetaxel. 
Based on these findings it was concluded that Tween 80 stabilized SLN surface modified 
with HBA and thiolated chitosan are the excellent carrier systems for brain targeting of 
docetaxel. These docetaxel formulations can be used in breast cancer induced brain 
metastasis 
Ropinirole Hydrochloride (RPN) is a hydrophilic drug, used in the treatment of Parkinson’s 
disease. It is a substrate for multidrug transporters, such as p-glycoprotein. It undergoes first 
pass metabolism and results in low bioavailability. Bioavailability of RPN varies between 
20-40% with inter-patient variability. Because of its hydrophilic nature and p-gp efflux, 
brain uptake of ropinirole is low. Hence, Ropinirole was selected as another drug with 
hydrophilic nature for brain targeting.  
Ropinirole loaded solid lipid nanoparticles were prepared using W/O/W double emulsion 
method. Because of its hydrophilic nature, drug used to come out of the nanoparticle after 
preparation of SLN. Hence, partition of drug form the formed nanoparticle to aqueous 
surfactant solution is greatly depends on the stabilizer used in the preparation of double 
emulsion. Hence, different external emulsifiers/stabilizers were used to optimize the 
formulation to give more stable formulation with minimum particle size and maximum 
entrapment efficiency. During the optimization, formulation variables such as concentration 
of lecithin or internal emulsifier, type and volume of organic solvent, concentration of 
external emulsifier and process variable such as sonication and homogenization time were 
optimized. Tween 80, Poloxamer and PVA with low and high molecular weights were used 
as external emulsifiers in the concentration of 0.5 to 2%.  Among these external stabilizers, 
1% PVA has shown minimum particle size (144.7±5.20 nm) with maximum entrapment 
efficiency (56.39±2.09%). Stability studies conducted at refrigerated temperature have 
shown that irrespective of type of emulsifier, all the formulations showed statistically 
significant increase (p<0.05) in particles compared with Day-1. But the percentage decrease 
(5%) was low with 1% PVA stabilized SLN. Eventhough high molecular weight PVA has 
also shown good stability, it resulted in large particles because of its high viscosity during 
the emulsification compared with low molecular weight PVA. Statistically insignificant 
difference in entrapment efficiency was observed even after three months with RPN-PVA.  
Crystallinity studies have shown decreased crystallinity of lipid, drug and formulation. 
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Hence, the drug was entrapped in the nanoparticles as amorphous form. The nature of drug 
dispersion in nanoparticle results in controlled release of drug from nanoparticles. The 
optimized 1% PVA stabilized ropinirole loaded SLN (RPN-PVA) was used for the surface 
modification with thiolated chitosan to improve the pharmacokinetic and tissue distribution 
profile of ropinirole. Because of negative zetapotential of RPN-PVA, thiolated chitosan was 
coated on RPN-PVA by electrostatic interaction. The surface modified RPN-PVA (TR-SLN) 
was characterized for particle size, zetapotential and entrapment efficiency. Particle size of 
Tr-SLN was significantly increased (156.43±3.71nm) compared with RPN-PVA formulation 
(p<0.05). This may be due to the surface coating of nanoparticles with the polymer. 
Zetapotential was changed from negative charge to positive charge, which is a sign for 
surface modification. Surface modification of TR-SLN was further confirmed using XPS 
analysis. XPS analysis has shown the presence of nitrogen and sulfur on the surface of 
nanoparticles and confirmed the surface modification of TPN-PVA with thiolated chitosan. 
Entrapment efficiency of TR-SLN was more compared with RPN-PVA.  Structure of TR-
SLN is like core shell model with surface coating. Hence there is a possibility for the 
accommodation of drug in between polymer and lipid surface. This may be the reason for 
the increased entrapment efficiency with TR-SLN. Crystallinity studies of TR-SLN also 
have also shown amorphous nature of drug present in the nanoparticles.  
In-vitro release studies conducted in simulated gastric fluid has shown burst release of 
ropinirole from the RPN-PVA and resulted in 20% of drug release in 24h. But, because 
surface coat present on the nanoparticles, TR-SLN has shown low percent (8%) drug release 
compared with RPN-PVA. But in SIF, both coated and un-coated formulations have shown 
controlled release of ropinirole.  Release of drug from nanoparticles followed Higuchi model 
with non-fickian type of diffusion. Both the SLN formulations have shown increased drug 
uptake in neuroblastoma cell lines. TR-SLN and RPN-PVA has shown seven times and four 
times more uptake of RPN compared with free drug respectively. But TR-SLN has shown 
two times more uptakes compared with RPN-PVA. Because of lipid nature of SLN, the 
uptake of drug was increased when the drug was incorporated in SLN. At the same time at 
BBB, p-gp efflux of drug also results in low uptake free drug. Hence, lipid nature coupled 
with p-gp inhibition property of TR-SLN resulted in more brain uptake compared with other 
formulations. 
In-vivo studies in rats after oral administration have shown statistically significant (p<0.01) 
increased plasma concentrations with SLN formulations compared with RPN. But the Tmax 
of formulation was shifted to 2h as compared with free drug, i.e., 1.5h. This is due to the 
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controlled release of drug from the formulation. TR-SLN resulted in 10 times increase in 
AUC compared with free drug. Because of more stability of TR-SLN in gastric milieu and 
inhibition of p-gp efflux with thiolated chitosan present on the surface of nanoparticles, 
AUC in plasma was significantly (p<0.05) increased compared with both RPN-PVA and free 
drug. TR-SLN was resulted in 7 times increase in brain concentrations compared with free 
drug. But, the drug concentration in brain was decreased rapidly in 4h and resulted in high 
drug concentration in other tissues.  
Base on these results it was concluded that surface modification of ropinirole loaded SLN 
with thiolated chitosan resulted in increased plasma levels as well as brain levels.  Thiolated 
chitosan coated SLN were excellent carrier systems with good stability for brain targeting 
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